Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 577

1.

Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.

Waksman R, Pakala R.

EuroIntervention. 2009 Dec 15;5 Suppl F:F36-42. doi: 10.4244/EIJV5IFA6. Review.

PMID:
22100674
3.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
4.
5.

Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design.

Tamburino C, Capodanno D, La Manna A, di Salvo M, Sanfilippo A, Prati F.

J Cardiovasc Med (Hagerstown). 2010 Jan;11(1):53-8. doi: 10.2459/JCM.0b013e32832ffad3.

PMID:
19829136
6.

Drug-eluting stents.

García-García HM, Vaina S, Tsuchida K, Serruys PW.

Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Review.

PMID:
17091802
7.
8.

Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.

Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrié D, Walsh S, Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ, Dawkins KD.

J Am Coll Cardiol. 2012 Apr 10;59(15):1362-70. doi: 10.1016/j.jacc.2011.12.016. Epub 2012 Feb 15.

9.

Atheroma and coronary bifurcations: before and after stenting.

Yazdani SK, Nakano M, Otsuka F, Kolodgie FD, Virmani R.

EuroIntervention. 2010 Dec;6 Suppl J:J24-30. doi: 10.4244/EIJV6SUPJA5. Review.

PMID:
21930487
10.

Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing.

Pendyala L, Jabara R, Robinson K, Chronos N.

J Interv Cardiol. 2009 Feb;22(1):37-48. doi: 10.1111/j.1540-8183.2009.00423.x. Review.

PMID:
19281521
11.

Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice?

Byrne RA, Kastrati A.

EuroIntervention. 2011 May;7 Suppl K:K47-52. doi: 10.4244/EIJV7SKA8.

PMID:
22027727
12.

Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.

Beijk MA, Klomp M, van Geloven N, Koch KT, Henriques JP, Baan J, Vis MM, Tijssen JG, Piek JJ, de Winter RJ.

Catheter Cardiovasc Interv. 2011 Aug 1;78(2):189-95. doi: 10.1002/ccd.23143. Epub 2011 Jul 15.

PMID:
21542109
13.

Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?

Valgimigli M, Airoldi F, Zimarino M.

J Cardiovasc Med (Hagerstown). 2009 Oct;10 Suppl 1:S17-26. doi: 10.2459/01.JCM.0000362040.25767.f5. Review.

PMID:
19851216
14.

Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.

Bonaventura K, Leber AW, Sohns C, Roser M, Boldt LH, Kleber FX, Haverkamp W, Dorenkamp M.

Clin Res Cardiol. 2012 Jul;101(7):573-84. doi: 10.1007/s00392-012-0428-2. Epub 2012 Feb 21.

PMID:
22350752
15.

Is there a higher risk of stent thrombosis in bifurcation lesion or is it related to the technique?

Iakovou I, Kadota K, Papamentzelopoulos S, Pavlides G, Mitsudo K.

EuroIntervention. 2010 Dec;6 Suppl J:J107-11. doi: 10.4244/EIJV6SUPJA17. Review.

PMID:
21930473
16.

Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating.

Jabara R, Chronos N, Robinson K.

Catheter Cardiovasc Interv. 2008 Aug 1;72(2):186-94. doi: 10.1002/ccd.21607.

PMID:
18651646
17.

One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.

Barthelemy O, Helft G, Silvain J, Bellemain-Appaix A, Beygui F, Choussat R, Berman E, Collet JP, Montalescot G, Metzger JP, Le Feuvre C.

Arch Cardiovasc Dis. 2011 Dec;104(12):604-10. doi: 10.1016/j.acvd.2011.05.010. Epub 2011 Nov 25.

18.

In-stent restenosis: the gold standard has changed.

Chin K.

EuroIntervention. 2011 May;7 Suppl K:K43-6. doi: 10.4244/EIJV7SKA7.

PMID:
22027726
19.

Stent thrombosis--risk assessment and prevention.

Motovska Z, Knot J, Widimsky P.

Cardiovasc Ther. 2010 Oct;28(5):e92-100. doi: 10.1111/j.1755-5922.2010.00186.x. Epub 2010 Jun 11. Review.

PMID:
20553282
20.

A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

PMID:
19377384

Supplemental Content

Support Center